Research Output Journal of Biological and Applied Science 6(1):69-76, 2026

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

https://doi.org/10.59298/ROJBAS/2026/616976

Theranostic Nanoplatforms for Obesity-Associated Diabetes: Combining Imaging and Therapy

Nalongo Bina K.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Obesity-associated diabetes (OAD), particularly type 2 diabetes (T2D), is a complex metabolic disorder characterized by insulin resistance, chronic inflammation, and dysregulated lipid metabolism. Early detection and personalized treatment strategies are crucial for effective management and prevention of complications. Theranostic nanoplatforms, which combine both therapeutic and diagnostic functions, offer a promising approach for managing OAD by enabling early diagnosis, monitoring disease progression, and delivering targeted therapies. These platforms integrate imaging agents for real-time monitoring with therapeutic agents aimed at modulating metabolic pathways. This review explores the role of theranostic nanoplatforms in the management of obesity-associated diabetes, focusing on their design, mechanisms of action, and applications in diagnosis and treatment. Challenges related to biocompatibility, targeting specificity, and clinical translation are also discussed, alongside future perspectives for advancing these nanoplatforms in clinical practice.

Keywords: theranostic nanoplatforms, obesity-associated diabetes, type 2 diabetes, imaging, therapy, insulin resistance

INTRODUCTION

Obesity is a leading global health issue that is closely associated with the development of insulin resistance (IR) and type 2 diabetes (T2D), collectively referred to as obesity-associated diabetes (OAD)[1–3]. The rising prevalence of obesity and T2D has created a significant burden on healthcare systems worldwide, with increasing rates of complications such as cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and diabetic neuropathy[4, 5-10]. In OAD, insulin resistance impairs glucose uptake in peripheral tissues, such as muscle, liver, and adipose tissue, leading to elevated blood glucose levels. At the same time, dysregulation of lipid metabolism, chronic inflammation, and oxidative stress further exacerbate the condition[11-16].

Early detection of insulin resistance and glucose dysregulation is critical for preventing the progression to overt diabetes and managing the associated complications. Currently, diagnostic methods for OAD primarily involve blood glucose testing, insulin sensitivity assays, and biomarker analysis[17-23]. However, these tests are often invasive, time-consuming, and lack the ability to detect early-stage metabolic dysfunction. Moreover, traditional therapies aimed at improving insulin sensitivity and glucose control often do not target the underlying causes of metabolic dysfunction, such as impaired adipose tissue function, mitochondrial dysfunction, and chronic low-grade inflammation[24-32].

To address these challenges, theranostic nanoplatforms have emerged as a promising strategy for the diagnosis and treatment of OAD. Theranostic platforms combine both therapeutic and diagnostic functions into a single system, enabling real-time monitoring of disease progression and the targeted delivery of therapeutics to specific tissues[33-38]. These nanoplatforms integrate imaging agents (such as fluorescent dyes, magnetic nanoparticles, or contrast agents) for monitoring disease markers with therapeutic agents (such as insulin-sensitizing drugs, anti-inflammatory agents, or lipid-regulating compounds) that can modulate metabolic pathways[39-45]. By combining imaging and therapy, theranostic nanoplatforms offer a personalized approach to managing OAD, allowing for continuous monitoring of disease progression and precise treatment delivery.

Lipid-based nanocarriers, polymeric nanoparticles, liposomes, and nanostructured lipid carriers (NLCs) are among the most commonly used platforms for theranostic applications in OAD[46-53]. These nanoplatforms can be designed to target specific tissues involved in metabolic dysfunction, such as adipose tissue, liver, and muscle, and can be loaded with bioactive agents that modulate lipid metabolism, glucose homeostasis, and inflammation. Furthermore, their ability to deliver drugs in a controlled and sustained manner enhances the therapeutic efficacy while minimizing side effects.

This review explores the potential of theranostic nanoplatforms in the management of OAD. We will discuss the design and mechanisms of action of these nanoplatforms, their applications in imaging and therapy, and the advantages of combining diagnostic and therapeutic functions. Additionally, we will address the challenges in translating theranostic nanoplatforms into clinical practice and explore future directions for improving these technologies [54-60].

2. Mechanisms of Action of Theranostic Nanoplatforms in OAD

Theranostic nanoplatforms are designed to combine diagnostic imaging and therapeutic capabilities, enabling real-time monitoring and targeted treatment of metabolic disorders such as obesity-associated diabetes (OAD)[61-68]. These platforms rely on a variety of mechanisms to enhance the precision and efficacy of both diagnosis and therapy. Key mechanisms of action include targeted delivery, enhanced bioavailability, sustained release, and the integration of imaging modalities to monitor disease progression and treatment outcomes.

Targeted Delivery to Insulin-Sensitive Tissues

A central feature of theranostic nanoplatforms is their ability to target specific tissues involved in metabolic dysfunction, such as adipose tissue, muscle, and liver[69-74]. This targeted delivery is achieved by functionalizing nanocarriers with ligands or surface modifications that bind to specific receptors overexpressed in these tissues. For example, fatty acid receptors (such as CD36) are overexpressed in adipose tissue and liver cells, making them ideal targets for lipid-based nanocarriers. Insulin receptors or GLUT4 transporters can also be targeted in insulin-resistant tissues to enhance glucose uptake[75-79].

By selectively delivering therapeutic agents (such as insulin-sensitizing drugs, anti-inflammatory agents, or lipid-lowering compounds) to insulin-resistant tissues, theranostic nanoplatforms can modulate lipid metabolism, reduce inflammation, and improve insulin sensitivity[80-86]. For instance, liposomal metformin has been shown to improve insulin sensitivity in adipose tissue by enhancing AMPK activation and reducing hepatic glucose production.

Enhanced Bioavailability and Stability

Many therapeutic agents used in the treatment of OAD suffer from poor bioavailability, instability, and rapid metabolism. Lipid-based nanocarriers, such as liposomes or solid lipid nanoparticles (SLNs), can encapsulate hydrophilic and hydrophobic drugs, improving their stability and solubility[87-93]. This enhances the bioavailability of therapeutic agents and ensures that they are delivered to the target tissues in effective concentrations[94-98].

For example, curcumin-loaded liposomes have been used to target inflammatory pathways in the liver and adipose tissue[28]. Curcumin, a potent antioxidant and anti-inflammatory compound, is poorly absorbed when administered orally. However, by encapsulating curcumin in lipid-based nanocarriers, its bioavailability is significantly enhanced, leading to reduced oxidative stress and improved glucose metabolism in obese and diabetic animal models[28–30].

Sustained Release of Therapeutic Agents

A significant advantage of theranostic nanoplatforms is their ability to provide sustained and controlled release of therapeutic agents. This feature is particularly important for treatments aimed at modulating glucose and lipid metabolism[14, 23]. Polymeric nanoparticles and NLCs can be engineered to release their payload in a controlled manner over an extended period, ensuring prolonged therapeutic effects with reduced dosing frequency[31–33].

For instance, liposomal pioglitazone, a drug used to improve insulin sensitivity, can be released over several days, allowing for sustained effects on lipid and glucose metabolism without the need for frequent dosing[34]. The controlled release of insulin-sensitizing drugs can lead to improved glycemic control and enhanced insulin sensitivity over time, reducing the risk of complications associated with T2D[34, 35].

Imaging Modalities for Real-Time Monitoring

Theranostic nanoplatforms integrate imaging agents to enable real-time monitoring of disease progression and therapeutic efficacy. These imaging agents can be optical, magnetic, or radioactive, depending on the imaging modality employed[36]. Fluorescent dyes, magnetic nanoparticles, and superparamagnetic iron oxide nanoparticles (SPIONs) are commonly used in theranostic nanoplatforms to monitor the accumulation of nanocarriers in target tissues and evaluate treatment outcomes[36, 37].

For example, magnetic resonance imaging (MRI) using SPIONs can track the distribution of theranostic nanocarriers in the liver and adipose tissue, providing valuable information about the effectiveness of treatment[38]. Similarly, fluorescence imaging can be used to monitor the uptake and retention of nanocarriers in specific tissues, allowing for real-time assessment of therapeutic effects[38].

3. Applications of Theranostic Nanoplatforms in OAD

Theranostic nanoplatforms have a wide range of applications in the diagnosis and treatment of obesity-associated diabetes (OAD), particularly in improving insulin resistance, lipid metabolism, and glucose homeostasis[39]. These platforms not only enable early detection and disease monitoring but also offer targeted therapy for modulating the underlying metabolic dysfunctions associated with OAD[39].

Early Diagnosis and Monitoring of Insulin Resistance

One of the major challenges in managing OAD is the difficulty in diagnosing insulin resistance and metabolic dysfunction in the early stages of the disease. Theranostic nanoplatforms can integrate imaging agents with metabolic probes to allow for early diagnosis of insulin resistance and metabolic disturbances before the onset of overt diabetes[40].

For example, magnetic resonance imaging (MRI) or positron emission tomography (PET) using theranostic nanocarriers that target fatty acid metabolism or glucose uptake can detect changes in adipose tissue and liver function in real-time[41]. Fluorescent-labeled nanocarriers can also provide visual insights into the distribution of insulin-resistant tissues, facilitating early detection and intervention.

Targeted Drug Delivery for Modulating Lipid Metabolism

Obesity and insulin resistance are closely linked to dysregulated lipid metabolism, particularly lipogenesis, fatty acid oxidation, and lipid accumulation in non-adipose tissues[42–45]. Theranostic nanoplatforms can deliver lipid-lowering agents such as statins, fibrates, and omega-3 fatty acids directly to adipose tissue or the liver, where they can modulate lipid metabolic pathways. These therapies can help reduce triglyceride levels, improve fatty acid oxidation, and reduce visceral fat accumulation, ultimately improving insulin sensitivity.

For instance, liposomal formulations of omega-3 fatty acids have been shown to reduce inflammation and oxidative stress in the liver, leading to improved glucose metabolism and insulin sensitivity in animal models of T2D. By delivering these agents to the liver and adipose tissue via theranostic nanoplatforms, the therapeutic efficacy is enhanced, and unwanted side effects are minimized[20, 39].

Real-Time Monitoring of Therapy and Disease Progression

Theranostic nanoplatforms enable real-time monitoring of the therapeutic effects of treatments aimed at improving insulin sensitivity and lipid metabolism[36]. By integrating imaging modalities with therapeutic agents, clinicians can assess the effectiveness of treatment regimens and make timely adjustments.

For example, fluorescence imaging or MRI using theranostic nanoplatforms can track changes in adipose tissue distribution, glucose uptake, and lipid content over the course of treatment[46]. This approach allows for a personalized treatment strategy, where therapy can be adjusted based on the patient's response to treatment, leading to better management of OAD.

4. Challenges and Future Directions

While theranostic nanoplatforms offer significant potential for the management of obesity-associated diabetes (OAD), several challenges remain in their development and clinical translation.

Biocompatibility and Safety

The biocompatibility and safety of theranostic nanoplatforms are paramount for their successful clinical application[47, 48]. Nanoparticles must be designed to minimize toxic effects and immune responses in the body. Long-term studies are needed to evaluate the biodegradability and clearance of nanoplatforms to prevent accumulation in tissues and potential adverse effects. Additionally, the size and surface charge of nanoparticles must be carefully optimized to ensure safe and efficient targeting without triggering immune activation[48].

Targeting Specificity

Achieving precise targeting of theranostic nanoplatforms to insulin-resistant tissues (adipose tissue, liver, muscle) is crucial for their therapeutic efficacy[49]. Nanocarriers must be functionalized with ligands that specifically bind to receptors overexpressed in these tissues. However, ensuring that nanoparticles selectively accumulate in target tissues without affecting non-target tissues is a major challenge. Advances in surface functionalization and the use of targeting ligands can improve the specificity of theranostic platforms.

Scalability and Manufacturing

The scalability and reproducibility of theranostic nanoplatform production are essential for their widespread clinical use[50]. Current methods for nanoparticle synthesis must be optimized for large-scale manufacturing while maintaining consistent quality and stability. Additionally, the production costs of theranostic nanoplatforms must be considered to ensure accessibility for patients[50].

Clinical Translation and Regulatory Approval

Despite promising preclinical data, theranostic nanoplatforms must undergo rigorous clinical trials to demonstrate their efficacy, safety, and long-term effects in humans. Regulatory agencies, such as the FDA and EMA, will need to establish clear guidelines for the approval of nanomedicines, which require extensive preclinical and clinical validation[51]. The cost-effectiveness of these platforms will also need to be evaluated to ensure their viability in routine clinical practice.

CONCLUSION

Theranostic nanoplatforms offer a revolutionary approach to the diagnosis and treatment of obesity-associated diabetes (OAD). By combining imaging and therapy, these platforms enable real-time monitoring of disease progression and targeted treatment of metabolic dysfunction. Lipid-based nanocarriers, such as liposomes, SLNs, and NLCs, can be engineered to deliver therapeutic agents that modulate lipid metabolism, glucose homeostasis, and insulin sensitivity, providing a dual approach to managing OAD. While significant challenges remain in terms of biocompatibility, targeting specificity, and clinical translation, theranostic nanoplatforms hold immense promise in improving the personalized treatment of OAD. Future research should focus on enhancing targeted delivery, reducing toxicity, and optimizing manufacturing processes to make these technologies accessible and effective in clinical practice. With continued advances in nanotechnology, theranostic platforms have the potential to transform the management of obesity, insulin resistance, and type 2 diabetes, offering more precise, efficient, and personalized therapies for these widespread metabolic disorders.

REFERENCES

1. Abbasi, M., Boka, D.A., DeLoit, H.: Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity. Pharmaceutics. 16, 1344 (2024). https://doi.org/10.3390/pharmaceutics16101344
2. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int. J. Mol. Sci. 25, 9715 (2024). https://doi.org/10.3390/ijms25179715
3. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
4. Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K., Bawa, I., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. Pharm. Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607
5. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
6. Bansal, S.K., Bansal, M.B.: Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10–S22 (2024). https://doi.org/10.1111/apt.17930
7. Bensussen, A., Torres-Magallanes, J.A., Roces De Álvarez-Buylla, E.: Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023). https://doi.org/10.3389/fimmu.2023.1014778
8. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
9. Mohd, S., Kumar, L.L., Harish, V., Kumar, R., Chaudhary, A., Sharma, V.: Diabetes mellitus: Complications, emerging therapeutic targets, and evolving treatment approaches. Obes. Med. 58, 100652 (2025). https://doi.org/10.1016/j.obmed.2025.100652
10. Zhang, J., Zhang, Z., Zhang, K., Ge, X., Sun, R., Zhai, X.: Early detection of type 2 diabetes risk: limitations of current diagnostic criteria. Front. Endocrinol. 14, 1260623 (2023). https://doi.org/10.3389/fendo.2023.1260623
11. Vaidya, R.A., Desai, S., Moitra, P., Salis, S., Agashe, S., Battalwar, R., Mehta, A., Madan, J., Kalita, S., Udipi, S.A., Vaidya, A.B.: Hyperinsulinemia: an early biomarker of metabolic dysfunction. Front. Clin. Diabetes Healthc. 4, (2023). https://doi.org/10.3389/fcdhc.2023.1159664
12. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
13. Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., Tong, N.: Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct. Target. Ther. 9, 262 (2024). https://doi.org/10.1038/s41392-024-01951-9
14. Andrew, J., Ezra-Manicum, A.-L., Witika, B.A.: Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer. EJNMMI Radiopharm. Chem. 9, 62 (2024). https://doi.org/10.1186/s41181-024-00295-7
15. Azimizonuzi, H., Ghayourvahdat, A., Ahmed, M.H., Kareem, R.A., Zrzor, A.J., Mansoor, A.S., Athab, Z.H., Kalavi, S.: A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis. Cancer Cell Int. 25, 26 (2025). https://doi.org/10.1186/s12935-024-03610-z
16. Chen, Z., Krishnamachary, B., Pachecho-Torres, J., Penet, M.-F., Bhujwalla, Z.M.: Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12, e1595 (2020). https://doi.org/10.1002/wnan.1595
17. Chen, F., Ehlerding, E.B., Cai, W.: Theranostic Nanoparticles. J. Nucl. Med. 55, 1919–1922 (2014). https://doi.org/10.2967/jnumed.114.146019
18. Gawne, P.J., Ferreira, M., Papaluca, M., Grimm, J., Decuzzi, P.: New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics. Nat. Rev. Mater. 8, 783–798 (2023). https://doi.org/10.1038/s41578-023-00581-x

19. Sankaranarayanan, S.A., Thomas, A., Revi, N., Ramakrishna, B., Rengan, A.K.: Iron oxide nanoparticles for theranostic applications - Recent advances. J. Drug Deliv. Sci. Technol. 70, 103196 (2022). https://doi.org/10.1016/j.jddst.2022.103196
20. Yasir, M., Mishra, R., Tripathi, A.S., Maurya, R.K., shahi, A., Zaki, M.E.A., Al Hussain, S.A., Masand, V.H.: Theranostics: a multifaceted approach utilizing nano-biomaterials. Discov. Nano. 19, 35 (2024). https://doi.org/10.1186/s11671-024-03979-w
21. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
22. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
23. Kevadiya, B.D., Woldstad, C., Ottemann, B.M., Dash, P., Sajja, B.R., Lamberty, B., Morsey, B., Kocher, T., Dutta, R., Bade, A.N., Liu, Y., Callen, S.E., Fox, H.S., Byrareddy, S.N., McMillan, J.M., Bronich, T.K., Edagwa, B.J., Boska, M.D., Gendelman, H.E.: Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics. 8, 256–276 (2018). https://doi.org/10.7150/thno.22764
24. Janib, S.M., Moses, A.S., MacKay, J.A.: Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62, 1052–1063 (2010). https://doi.org/10.1016/j.addr.2010.08.004
25. Karakasis, P., Theofilis, P., Vlachakis, P.K., Grigoriou, K., Patoulias, D., Antoniadis, A.P., Fragakis, N.: Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics. 17, 1028 (2025). https://doi.org/10.3390/pharmaceutics17081028
26. Viegas, C., Seck, F., Fonte, P.: An insight on lipid nanoparticles for therapeutic proteins delivery. J. Drug Deliv. Sci. Technol. 77, 103839 (2022). https://doi.org/10.1016/j.jddst.2022.103839
27. Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J.L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., Ma, Y.: Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs. Drug Des. Devel. Ther. 18, 1469–1495 (2024). https://doi.org/10.2147/DDDT.S447496
28. Yavarpour-Bali, H., Ghasemi-Kasman, M., Pirzadeh, M.: Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomedicine. 14, 4449–4460 (2019). https://doi.org/10.2147/IJN.S208332
29. Hamed, A.M., Elbahy, D.A., Ahmed, A.RH., Thabet, S.A., Refaei, R.A., Ragab, I., Elmahdy, S.M., Osman, A.S., Abouelella, A.MA.: Comparison of the efficacy of curcumin and its nano formulation on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in Wistar rats. Heliyon. 10, e41043 (2024). https://doi.org/10.1016/j.heliyon.2024.e41043
30. Kunnumakkara, A.B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U.D., Garodia, P., Yenisetti, S.C., Oommen, O.V., Aggarwal, B.B.: Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials. ACS Pharmacol. Transl. Sci. 6, 447–518 (2023). https://doi.org/10.1021/acsptsci.2c00012
31. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
32. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
33. Zhang, W., Mehta, A., Tong, Z., Esser, L., Voelcker, N.H.: Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges. Adv. Sci. 8, 2003937 (2021). https://doi.org/10.1002/advs.202003937
34. Clark, M., Thomaseth, K., Dirikolu, L., Ferguson, D.C., Hoenig, M.: Effects of Pioglitazone on Insulin Sensitivity and Serum Lipids in Obese Cats. J. Vet. Intern. Med. 28, 166–174 (2014). https://doi.org/10.1111/jvim.12255
35. Zhang, Y., Wang, T., Han, J., Song, J., Yang, C., Liang, L., Li, H., Wang, H.: Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease. Front. Pharmacol. 16, (2025). https://doi.org/10.3389/fphar.2025.1610498
36. Salgueiro, M.J., Zubillaga, M.: Theranostic Nanoplatforms in Nuclear Medicine: Current Advances, Emerging Trends, and Perspectives for Personalized Oncology. J. Nanotheranostics. 6, 27 (2025). https://doi.org/10.3390/jnt6040027
37. Shanahan, K., Coen, D., Nafo, W.: Polymer-based nanoparticles for cancer theranostics: advances, challenges, and future perspectives. Explor. BioMat-X. 2, 101342 (2025). https://doi.org/10.37349/ebmx.2025.101342

38. Rahman, M.: Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine. Nanotheranostics. 7, 424–449 (2023). https://doi.org/10.7150/ntno.86467
39. Li, J., Cha, R., Luo, H., Hao, W., Zhang, Y., Jiang, X.: Nanomaterials for the theranostics of obesity. Biomaterials. 223, 119474 (2019). https://doi.org/10.1016/j.biomaterials.2019.119474
40. Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Feng, C., Mi, J., Pan, H., Wu, J., Huang, B., Wu, A.: Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. J. Nanobiotechnology. 23, 682 (2025). https://doi.org/10.1186/s12951-025-03677-4
41. Carpentier, A.C.: Tracers and Imaging of Fatty Acid and Energy Metabolism of Human Adipose Tissues. Physiology. 39, 61–72 (2024). https://doi.org/10.1152/physiol.00012.2023
42. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
43. MacDonald-Ramos, K., Monroy, A., Bobadilla-Bravo, M., Cerbón, M.: Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. Int. J. Mol. Sci. 25, 2050 (2024). https://doi.org/10.3390/ijms25042050
44. Roy, P.K., Islam, J., Lalhlenmawia, H.: Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance. Egypt. Heart J. 75, 24 (2023). https://doi.org/10.1186/s43044-023-00352-7
45. Yazıcı, D., Sezer, H.: Insulin Resistance, Obesity and Lipotoxicity. Adv. Exp. Med. Biol. 960, 277–304 (2017). https://doi.org/10.1007/978-3-319-48382-5_12
46. Nag, S., Mitra, O., Maturi, B., Kaur, S.P., Saini, A., Nama, M., Roy, S., Samanta, S., Chacko, L., Dutta, R., Sayana, S.B., Subramaniyan, V., Bhatti, J.S., Kandimalla, R.: Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics. Asian J. Pharm. Sci. 19, 100927 (2024). https://doi.org/10.1016/j.ajps.2024.100927
47. Elmowafy, E.M., Tiboni, M., Soliman, M.E.: Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. 49, 347–380 (2019). https://doi.org/10.1007/s40005-019-00439-x
48. Kyriakides, T.R., Raj, A., Tseng, T.H., Xiao, H., Nguyen, R., Mohammed, F.S., Halder, S., Xu, M., Wu, M.J., Bao, S., Sheu, W.C.: Biocompatibility of nanomaterials and their immunological properties. Biomed. Mater. Bristol Engl. 16, 10.1088/1748-605X/abe5fa (2021). https://doi.org/10.1088/1748-605X/abe5fa
49. Chen, Y.-N., Li, M.-Q., Zhang, H.-J., Xu, N.-N., Xu, Y.-Q., Liu, W.-X., Chen, T.-T., Li, N., Wu, G.-Y., Zhao, J.-M., Sun, W.-Y.: Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis. Int. J. Pharm. X. 10, 100411 (2025). https://doi.org/10.1016/j.ijpx.2025.100411
50. Elendu, C., Amaechi, D.C., Elendu, T.C., Amaechi, E.C., Elendu, I.D., Omeludike, J.C., Omeludike, E.K., Onubogu, N.C., Ogelle, E.C., Meduoye, O.O.M., Oloyede, P.O., Ezeh, C.P., Esangbedo, I.J., Adigwe, A.C., Akuma, N.M., Okafor, S.U.: Essential information about nanotechnology in cardiology. Ann. Med. Surg. 87, 748–779 (2025). https://doi.org/10.1097/MS9.0000000000002867
51. Kumarasamy, R.V., Natarajan, P.M., Umapathy, V.R., Roy, J.R., Mironescu, M., Palanisamy, C.P.: Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Front. Nanotechnol. 6, (2024). https://doi.org/10.3389/fnano.2024.1479993
52. Isaac Edyedu PMA, Ugwu OPC, Ugwu CN, Alum EU, et al. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. Medicine. 2025;104(7):e41381.
53. Alum EU, Ugwu OPC, Obeagu EI, et al. Nutritional care in diabetes mellitus: A comprehensive guide. Int J Innov Appl Res. 2023;11(12):16-25.
54. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OPC, Alum EU. Biomarkers of breast cancer: Overview. Int J Curr Res Biol Med. 2023;1:8-16.
55. Uti DE, Alum EU, Atangwho IJ, Ugwu OPC, et al. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: Advances in targeted delivery and precision therapeutics. J Nanobiotechnol. 2025;23:336.
56. Ugwu CN, Ugwu OPC, Alum EU, Eze VHU, Basajja M, Ugwu JN, Ogenyi FC, et al. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. Medicine. 2025;104(18):e42289.
57. Obeagu EI, Scott GY, Amekpor F, Ugwu OPC, Alum EU. COVID-19 infection and diabetes: A current issue. Int J Innov Appl Res. 2023;11(1):25-30.
58. Offor CE, Ugwu OPC, Alum EU. Anti-diabetic effect of ethanol leaf extract of *Allium sativum* on albino rats. Int J Pharm Med Sci. 2014;4(1):1-3.
59. Asogwa FC, Okechukwu PCU, Esther UA, Chinedu OE, Nzubechukwu E. Hygienic and sanitary assessment of street food vendors in selected towns of Enugu North District, Nigeria. Am-Eurasian J Sci Res. 2015;10(1):22-26.

60. Alum EU, Uti DE, Agah VM, Orji OU, Nkeiru N, et al. Physico-chemical and bacteriological analysis of water used for drinking and domestic purposes in Amaozara Ozizza, Afikpo North, Nigeria. Niger J Biochem Mol Biol. 2023;38(1):1-8.
61. Ugwu OPC, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine. 2024;103(19):e38088.
62. Ezekwe CI, Uzomba CR, Ugwu OPC. Effect of methanol extract of *Talinum triangulare* on hematology and liver parameters in rats. Glob J Biotechnol Biochem. 2013;8(2):51-60.
63. Alum EU, Inya JE, Ugwu OPC, Obeagu EI, Aloke C, Aja PM, Okpata MG, et al. Ethanolic leaf extract of *Datura stramonium* attenuates methotrexate-induced biochemical alterations in Wistar rats. RPS Pharmacol Rep. 2023;2(1):1-6.
64. Ugwu OPC, Erisa K, Inyangat R, Obeagu EI, et al. Indigenous medicinal plants for managing diabetes in Uganda: Ethnobotanical and pharmacotherapeutic insights. INOSR Exp Sci. 2023;12(2):214-224.
65. Alum EU, Aja W, Ugwu OPC. Vitamin composition of ethanol leaf and seed extracts of *Datura stramonium.* Avicenna J Med Biochem. 2023;11(1):92-97.
66. Ezenwaji CO, Alum EU, Ugwu OPC. Digital health in pandemic preparedness and response: Securing global health? Glob Health Action. 2024;17(1):2419694.
67. Adonu CC, Ugwu OP, Bawa A, Ossai EC, Nwaka AC. Intrinsic blood coagulation studies in patients with diabetes and hypertension. Int J Pharm Med Bio Sci. 2013;2(2):36-45.
68. Offor CE, Ugwu PC, Okechukwu PM, Igwenyi IO. Proximate and phytochemical analyses of *Terminalia catappa* leaves. Eur J Appl Sci. 2015;7(1):9-11.
69.Enechi YS, Ugwu OC, Ugwu KK, Ugwu OPC, Omeh N. Evaluation of antinutrient levels of *Ceiba pentandra* leaves. IJRRPAS. 2013;3(3):394-400.
70.Alum EU, Uti DE, Ugwu OPC, Alum BN, Edeh FO, Ainebyoona C. Microbiota in cancer development and treatment. Discov Oncol. 2025;16(1):646.
71. Asogwa FC, Okoye COB, Ugwu OPC, Edwin N, Alum EU, Egwu CO. Phytochemistry and antimicrobial assay of *Jatropha curcas* extracts. Eur J Appl Sci. 2015;7(1):12-16.
72. Enechi OC, Oluka HI, Ugwu PCO. Acute toxicity and ameliorative properties of *Alstonia boonei* leaf extract on diabetic rats. Afr J Biotechnol. 2014;13(5).
73.Alum EU, Obeagu EI, Ugwu OPC. Enhancing water, sanitation, and hygiene for diarrhoea control and SDGs: A review. Medicine. 2024;103(38):e39578.
74. Odo CE, Nwodo OFC, Joshua PE, Ugwu OPC, Okonkwo CC. Anti-diarrhoeal effect of chloroform–methanol extract of *Persea americana* seeds in rats. J Pharm Res. 2013;6(3):331-335.
75. Ugwu OPC, Obeagu EI, Alum EU, Michael M, et al. Effect of ethanol leaf extract of *Chromolaena odorata* on hepatic markers in diabetic rats. IAA J Appl Sci. 2023;9(1):46-56.
76. Ibiam UA, Alum EU, Orji OU, Aja PM, Nwamaka EN, Ugwu OPC, et al. Anti-inflammatory effects of *Buchholzia coriacea* leaf extract in arthritic rats. Indo Am J Pharm Sci. 2018;5(7):6341-6357.
77. Obeagu EI, Obeagu GU, Odo EO, Alum EU. Nutritional approaches for enhancing immune competence in HIV-positive individuals. IDOSR J Appl Sci. 2024;9(1):40-50.
78. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: Gatekeeper of iron in malaria resistance. Newport Int J Res Med Sci. 2023;4(2):1-8.
79. Nyamboga TO, Ugwu OPC, Ugwu JN, et al. Biotechnological innovations in soil health management: a systematic review of integrating microbiome engineering, bioinformatics, and sustainable practices. Cogent Food Agric. 2025;11(1):2519811.
80. Madu ANB, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Ukaidi CUA. The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. Medicine. 2025;104(18):e42300.
81. Alum EU, Ugwu OPC. Beyond pregnancy: Understanding long-term implications of gestational diabetes mellitus. INOSR Sci Res. 2024;11(1):63-71.
82. Ugwu OPC, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and GC-MS analysis of ethanol root extract and fractions of *Sphenocentrum jollyanum.* RPS Pharmacol Pharm Rep. 2023;2(2):rqad007.
83. Eze VHU, Eze CE, Mbabazi A, Ugwu CN, Ugwu PO, Ogenyi CF, Ugwu JN, et al. Qualities and characteristics of a good scientific research writing: Step-by-step approaches. IAA J Appl Sci. 2023;9(2):71-76
84. Igwenyi IO, Nchi PO, Okechukwu UPC, Igwenyi IP, Obasi DC, Edwin N. Nutritional potential of *Azadirachta indica* seeds. Indo Am J Pharm Sci. 2017;4(2):477-482.
85. Enechi OC, Oluka IH, Ugwu OPC, Omeh YS. Effect of ethanol leaf extract of *Alstonia boonei* on lipid profile of alloxan-induced diabetic rats. Afr J Biotechnol. 2013;24.
86. Ugwu OPC. Anti-malaria effect of ethanol extract of *Moringa oleifera* leaves on malaria-induced mice. University of Nigeria Nsukka; 2011:39.

87. Alum EU, Ugwu OPC, Obeagu EI. Nutritional interventions for cervical cancer patients: Beyond conventional therapies. J Cancer Res Cell Ther. 2024;8(1):1-6.
88. Obeagu EI, Obeagu GU. Advancements in immune augmentation strategies for HIV patients. IAA J Biol Sci. 2024;11(1):1-11.
89. Okechukwu PU, Nzubechukwu E, Ogbanshi ME, Ezeani N, Nworie MO. Effect of ethanol leaf extract of *Jatropha curcas* on chloroform-induced hepatotoxicity in albino rats. Glob J Biotech Biochem. 2015;10:11-15.
90. Ilozue NM, Ikezu UP, Okechukwu PCU. Antimicrobial and phytochemical screening of *Persea americana* seed extracts. IOSR J Pharm Biol Sci. 2014;9(2):23-25.
91. Onyeze R, Udeh SM, Akachi B, Ugwu OP. Isolation and characterization of fungi associated with spoilage of corn (*Zea mays*). Int J Pharm Med Biol Sci. 2013;2(3):86-91.
92. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: The gatekeeper of iron in malaria resistance. Newport Int J Res Med Sci. 2023;4:1-8.
93. Obeagu EI, Alum EU, Obeagu GU, Ugwu OPC. Prostate cancer: Review on risk factors. Eurasian Exp J Public Health. 2023;4(1):4-7.
94.Offor CE, Okaka ANC, Ogbugo SO, Egwu CO, Okechukwu PC. Effects of ethanol leaf extract of *Pterocarpus santalinoides* on haemoglobin, packed cell volume and platelets. IOSR J Nurs Health Sci. 2015;4:108-112, 93.
95. Offor C, Aja PC, Ugwu O, Agbafor KN. Effects of ethanol leaf extract of *Gmelina arborea* on serum proteins in albino rats. Glob J Environ Res. 2015;9(1):1-4.
96. Alum EU, Uti DE, Obeagu EI, Ugwu OPC, Alum BN. Cancer's psychosocial aspects: Impact on patient outcomes. Elite J Med. 2024;2(6):32-42.
97. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate variability and malaria transmission: Unravelling the complex relationship. INOSR Sci Res. 2024;11(2):16-22.
98. Alum EU, Obeagu EI, Ugwu OPC, Egba SI, EjimUti DE, Ukaidi CUA, et al. Confronting dual challenges: Substance abuse and HIV/AIDS. Elite J HIV. 2024;2(5):1-8.

CITE AS: Nalongo Bina K. (2026). Theranostic Nanoplatforms for Obesity-Associated Diabetes: Combining Imaging and Therapy. Research Output Journal of Biological and Applied Science 6(1):69-76. https://doi.org/10.59298/ROJBAS/2026/616976